BetterLife Pharma Inc. announced it has completed its 4-week oral BETR-001 GLP toxicology study in animals. The study demonstrated that BETR-001's repeated dosing for 4 weeks is very well-tolerated. The study findings support a broad therapeutic window for the use of BETR-001 in humans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.085 USD | +0.71% | -2.30% | +77.08% |
May. 14 | BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 | CI |
May. 03 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+77.08% | 9.97M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001